BIOMÉRIEUX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101.5 EUR | +2.01% |
|
+1.96% | +0.89% |
| 26/04 | BioMérieux: share price rises, analyst remains Buy | CF |
| 26/04 | BIOMÉRIEUX : Berenberg raises its target | CF |
| Sales 2024 * | 3.9B 4.17B 348B | Sales 2025 * | 4.19B 4.48B 374B | Capitalization | 11.99B 12.82B 1,070B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 498M 41.56B | Net income 2025 * | 525M 561M 46.82B | EV / Sales 2024 * | 2.98 x |
| Net cash position 2024 * | 347M 371M 30.95B | Net cash position 2025 * | 487M 521M 43.46B | EV / Sales 2025 * | 2.74 x |
| P/E ratio 2024 * |
26.1
x | P/E ratio 2025 * |
23.2
x | Employees | 13,696 |
| Yield 2024 * |
0.86% | Yield 2025 * |
0.99% | Free-Float | 36.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More press releases
More news
| 1 day | +2.01% | ||
| 1 week | +1.96% | ||
| Current month | -0.73% | ||
| 1 month | +0.79% | ||
| 3 months | -3.29% | ||
| 6 months | +17.12% | ||
| Current year | +0.89% |
1 week
98.65
102.90
1 month
94.60108.90
Current year
94.26108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 01/16/01 |
| Chairman | 50 | 16/04/16 | |
| Director of Finance/CFO | 47 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 15/06/15 | |
| Director/Board Member | 63 | 01/05/01 | |
| Chairman | 50 | 16/04/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 16 M€ | -8.49% | ||
| 0.26% | 1,120 M€ | +0.40% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 101.5 | +2.01% | 93,439 |
| 25/24/25 | 99.5 | -1.19% | 60,768 |
| 24/24/24 | 100.7 | -0.69% | 97,428 |
| 23/24/23 | 101.4 | +0.70% | 85,555 |
| 22/24/22 | 100.7 | +1.16% | 63,133 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
23/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
101.5
EUR
Average target price
112.8
EUR
Spread / Average Target
+11.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- BIM Stock
